Immunocore announces two new PRAME ImmTAC candidates

PRISM-MEL301 – First PRAME Phase 3 clinical trial with IMC-F106C in first-line advanced cutaneous melanoma: In August 2023, the Company announced plans to start a registrational Phase 3 trial with IMC-F106C in cutaneous melanoma. The trial will randomize patients with HLA-A*02:01-positive, first-line advanced cutaneous melanoma to IMC-F106C + nivolumab versus a control arm of either nivolumab or nivolumab + relatlimab, depending on the country where the patient is enrolled. The Company plans to randomize the first patient in this trial in the first quarter of 2024. Phase 1/2 clinical trial of IMC-F106C targeting PRAME-A02 in multiple solid tumors: In addition to progressing IMC-F106C into a registrational trial in cutaneous melanoma, the Company is continuing to enroll patients in the monotherapy and combination arms of the Phase 1/2 clinical trial across multiple tumor types, including expansion arms for patients with advanced ovarian, non-small cell lung carcinoma, endometrial, and melanoma. In August 2023, the Company provided an updated analysis of the original 18 melanoma patients, which continued to show promising durability of the clinical activity. The Company expects to report clinical data from the ongoing monotherapy and combination cohorts throughout 2024 including cutaneous melanoma, ovarian, and non-small cell lung carcinoma. IMC-P115C & IMC-T119C. The Company is expanding the PRAME franchise with two new PRAME ImmTAC candidates, IMC-P115C and IMC-T119C for solid tumors, which are both on track for investigational new drug or clinical trial application submissions for IMC-P115C in the second quarter of 2024 and the second half of 2024 for IMC-T119C.